In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cequent Pharmaceuticals Inc.

Division of Marina Biotech Inc.
www.marinabio.com

Latest From Cequent Pharmaceuticals Inc.

Ensemble makes management appointment

The US-based biotechnology company Ensemble Therapeutics has named Ted Hibben senior vice-president of corporate development. He was most recently chief business officer of Cequent Pharmaceuticals (now part of Marina Biotech. Before that, Mr Hibben was vice-president of business development and alliance management at Coley Pharmaceutical (which was acquired by Pfizer in 2008).

Companies

Deals Shaping the Medical Industry (05/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Start-Ups Against Inflammation

Inflammation plays a part in a wide range of diseases across a broad spectrum of markets, including the huge and already crowded, like rheumatoid arthritis; the difficult to navigate, like Crohn's disease; and the emerging, like atherosclerosis. Start-ups looking to compete in inflammation can boost their chances of success by focusing on niche indications or on drug targets with broad applicability, and thus attract the attention of in-licensers or acquirers. In this issue, we profile four young companies hoping to prove the worth of their technologies to investors and partners alike.
BioPharmaceutical

The A-List: 2007's Trend Shaping Series A Financings

In 2007, what did Series A venture investments reveal about the state of the health care industry? It was very healthy, thank you. There were quite a few deals to choose from, and numbers demonstrated continued growth in diagnostics fundraising, a resurgence in vaccines, and evidence of pharma's interest in proof-of-concept projects and large-molecule platforms. Medical device investors, meanwhile, remain enamored with concept companies seeking to blend electronics-such as neurostimulation or miniature sensors-with devices.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Marina Biotech Inc.
  • Senior Management
  • Peter D Parker, Pres. & CEO
    Lisa A Velardo, CFO
    Allison Silva, VP, Drug Dev.
  • Contact Info
  • Cequent Pharmaceuticals Inc.
    Phone: (617) 995-7940
    1 Kendall Sq., Bldg. 700
    1st Fl.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register